524212 Stock Overview
Manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Wanbury Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹259.95 |
52 Week High | ₹291.00 |
52 Week Low | ₹88.00 |
Beta | 0.53 |
11 Month Change | 3.65% |
3 Month Change | 28.85% |
1 Year Change | 195.40% |
33 Year Change | 227.60% |
5 Year Change | 1,763.44% |
Change since IPO | 39.50% |
Recent News & Updates
Recent updates
Shareholder Returns
524212 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 7.1% | -0.6% | 0.8% |
1Y | 195.4% | 51.3% | 36.2% |
Return vs Industry: 524212 exceeded the Indian Pharmaceuticals industry which returned 51.3% over the past year.
Return vs Market: 524212 exceeded the Indian Market which returned 36.2% over the past year.
Price Volatility
524212 volatility | |
---|---|
524212 Average Weekly Movement | 7.5% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.3% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524212 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524212's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 1,491 | Mohan Rayana | www.wanbury.com |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury Limited Fundamentals Summary
524212 fundamental statistics | |
---|---|
Market cap | ₹8.41b |
Earnings (TTM) | ₹523.05m |
Revenue (TTM) | ₹5.60b |
16.3x
P/E Ratio1.5x
P/S RatioIs 524212 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524212 income statement (TTM) | |
---|---|
Revenue | ₹5.60b |
Cost of Revenue | ₹2.84b |
Gross Profit | ₹2.77b |
Other Expenses | ₹2.24b |
Earnings | ₹523.05m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 13, 2024
Earnings per share (EPS) | 15.97 |
Gross Margin | 49.35% |
Net Profit Margin | 9.33% |
Debt/Equity Ratio | 416.9% |
How did 524212 perform over the long term?
See historical performance and comparison